on Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Develop Peptide-Conjugated Antisense Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. have announced a new collaboration aimed at discovering and developing peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
The partnership will leverage Orbit’s expertise in peptide discovery to identify and screen cyclic peptides, which will be combined with Secarna’s proprietary ASO molecules. This new approach aims to expand Secarna’s therapeutic capabilities beyond antibodies and sugar molecules.
Konstantin Petropoulos, CBO of Secarna Pharmaceuticals, expressed enthusiasm, stating the collaboration will enhance their development capabilities for targeted antisense therapeutics. Dr. Neil Butt, CEO of Orbit Discovery, echoed this sentiment, highlighting the potential for safer and more effective therapies.
The collaboration is expected to strengthen the creation of targeted antisense therapeutics and could potentially offer new treatment options for a wider range of diseases.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Secarna Pharmaceuticals GmbH & Co. KG news